published meta-analysis   sensitivity analysis   studies

first booster dose in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias confirmed COVID (any severity)detailed resultsAbu-Raddad, 2022 0.53 [0.47; 0.59] Tan, 2022 0.20 [0.14; 0.27] 0.33[0.12; 0.86]Abu-Raddad, 2022, Tan, 2022297%NAnot evaluable symptomatic Covid-19detailed resultsAbu-Raddad, 2022 0.53 [0.47; 0.59] 0.53[0.47; 0.59]Abu-Raddad, 202210%NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-06-01 04:50 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 1088,1331,1330,1329,1344,1328,1327 - roots T: 290